Schedule 13G Filing for Zenas BioPharma, Inc.

InnoCare Pharma Inc., Ocean Prominent Limited, and InnoCare Pharma Limited have jointly filed a Schedule 13G with the SEC, disclosing their beneficial ownership of common stock in Zenas BioPharma, Inc. The filing indicates that the Reporting Persons collectively own 5,000,000 shares, representing 9.4% of the outstanding common stock. The shares are directly held by InnoCare Pharma Inc., which is a wholly owned subsidiary of Ocean Prominent Limited, which in turn is a wholly owned subsidiary of InnoCare Pharma Limited. The Reporting Persons have explicitly disclaimed status as a 'group' for the purposes of this filing. The filing was made pursuant to Rule 13d-1(c) and includes a Joint Filing Agreement signed by Jisong Cui on behalf of all Reporting Persons.